S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.

Detalles Bibliográficos
Autores principales: Duarte, Rafael F, Alain, Sophie, Chemaly, Roy F, Montoto, Carmen, de Castro-Orós, Isabel, Maertens, Johan, Tagarro, Ignacio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Oral Sessions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428459/
http://dx.doi.org/10.1097/01.HS9.0000968088.69924.4d
_version_ 1785090474475782144
author Duarte, Rafael F
Alain, Sophie
Chemaly, Roy F
Montoto, Carmen
de Castro-Orós, Isabel
Maertens, Johan
Tagarro, Ignacio
author_facet Duarte, Rafael F
Alain, Sophie
Chemaly, Roy F
Montoto, Carmen
de Castro-Orós, Isabel
Maertens, Johan
Tagarro, Ignacio
author_sort Duarte, Rafael F
collection PubMed
description
format Online
Article
Text
id pubmed-10428459
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104284592023-08-17 S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS. Duarte, Rafael F Alain, Sophie Chemaly, Roy F Montoto, Carmen de Castro-Orós, Isabel Maertens, Johan Tagarro, Ignacio Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428459/ http://dx.doi.org/10.1097/01.HS9.0000968088.69924.4d Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Oral Sessions
Duarte, Rafael F
Alain, Sophie
Chemaly, Roy F
Montoto, Carmen
de Castro-Orós, Isabel
Maertens, Johan
Tagarro, Ignacio
S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.
title S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.
title_full S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.
title_fullStr S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.
title_full_unstemmed S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.
title_short S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.
title_sort s294: maribavir (mbv) versus investigator-assigned therapy for refractory cytomegalovirus (cmv) infection: subgroups analyses of phase 3 study by resistance status knowledge reported by investigators.
topic Oral Sessions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428459/
http://dx.doi.org/10.1097/01.HS9.0000968088.69924.4d
work_keys_str_mv AT duarterafaelf s294maribavirmbvversusinvestigatorassignedtherapyforrefractorycytomegaloviruscmvinfectionsubgroupsanalysesofphase3studybyresistancestatusknowledgereportedbyinvestigators
AT alainsophie s294maribavirmbvversusinvestigatorassignedtherapyforrefractorycytomegaloviruscmvinfectionsubgroupsanalysesofphase3studybyresistancestatusknowledgereportedbyinvestigators
AT chemalyroyf s294maribavirmbvversusinvestigatorassignedtherapyforrefractorycytomegaloviruscmvinfectionsubgroupsanalysesofphase3studybyresistancestatusknowledgereportedbyinvestigators
AT montotocarmen s294maribavirmbvversusinvestigatorassignedtherapyforrefractorycytomegaloviruscmvinfectionsubgroupsanalysesofphase3studybyresistancestatusknowledgereportedbyinvestigators
AT decastroorosisabel s294maribavirmbvversusinvestigatorassignedtherapyforrefractorycytomegaloviruscmvinfectionsubgroupsanalysesofphase3studybyresistancestatusknowledgereportedbyinvestigators
AT maertensjohan s294maribavirmbvversusinvestigatorassignedtherapyforrefractorycytomegaloviruscmvinfectionsubgroupsanalysesofphase3studybyresistancestatusknowledgereportedbyinvestigators
AT tagarroignacio s294maribavirmbvversusinvestigatorassignedtherapyforrefractorycytomegaloviruscmvinfectionsubgroupsanalysesofphase3studybyresistancestatusknowledgereportedbyinvestigators

Ejemplares similares